share_log

Morgan Stanley Maintains Overweight on IO Biotech, Lowers Price Target to $7

Benzinga ·  Aug 15, 2023 09:00

Morgan Stanley analyst Matthew Harrison maintains IO Biotech (NASDAQ:IOBT) with a Overweight and lowers the price target from $11 to $7.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment